Korean J Gastroenterol.  2023 Aug;82(2):105-106. 10.4166/kjg.2023.070.

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)

• Choe JW

• KMID: 2545336
• DOI: http://doi.org/10.4166/kjg.2023.070

Reference

1. Oh DY, Ruth He A, Qin S, et al. 2022; Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1:EVIDoa2200015. DOI: 10.1056/EVIDoa2200015.

2. Burris III HA, Okusaka T, Vogel A, et al. 2022; Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. J Clin Oncol. 40(16 Suppl):4070. DOI: 10.1200/JCO.2022.40.16_suppl.4070.

3. Zhao Q, Xie R, Zhong W, et al. 2023; Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost Eff Resour Alloc. 21:19. DOI: 10.1186/s12962-023-00429-9. PMID: 36859267. PMCID: PMC9979442.

4. Kelley RK, Ueno M, Yoo C, et al. 2023; Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401:1853–1865. DOI: 10.1016/S0140-6736(23)00727-4. PMID: 37075781.